Atricure, Inc. · NASDAQ:ATRC
Atricure — Investor Presentation (September 2022)
7 slides from Atricure's investor presentation, September 2022
Slide 1: Creating a World Class Afib Platform
Creating a World Class Afib Platform INVESTOR EDUCATION: HYBRID AF THERAPY SEPTEMBER 2022 © 2022 AtriCure, Inc. All rights reserved.
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation and oral statements made in connection with this presentation contain “forward-looking statements,” which are statements related to future events that by their nature address matters that are uncertain. Forward-looking statements address, among other thin
Slide 3: We are passionately focused on reducing the global Afib epidemic
We are Large Markets Addressing an underserved and passionately growing patient population focused on reducing the Strong Portfolio Existing products and solutions global Afib driving consistent growth epidemic and healing the lives Bright Future Novel therapies supported by of those affected growin
Slide 4: CONVERGE: Long-standing Persistent Afib Patient Analysis
CONVERGE: Long-standing Persistent Afib Patient Analysis Freedom from AF/AFL/AT from 3-month blanking period through 12-months and 18-months 100% 90% 29% differential 35% differential • Superior outcomes with hybrid Convergent ~78% improvement >100% improvement procedure when compared to endocardial
Slide 5: Afib: A Serious Problem
Afib: A Serious Problem Atrial Fibrillation (Afib) is an irregular heartbeat (or arrhythmia) that affects more than 37 million people worldwide. 1 8 Million 2 8 Million 3.5 Million 1 in 4 Adults People estimated to have long-standing People estimated to have Afib in the US2 Over 40 will develop Afib
Slide 6: Thank You!
Thank You! © 2022 AtriCure, Inc. All rights reserved.
Slide 7: References and Abbreviations
References and Abbreviations Note Reference 1 European Heart Journal – Quality of Care and Clinical Outcomes (2021) 7, 574-582 doi: 10.1093/ehjqcco/qcaa061 2 The American Journal of Cardiology (2013), 112: 1142-1147 Medical management estimate: Colilia, et al. Estimates of Current and Future Inciden